TransMedics Group (NASDAQ:TMDX) Price Target Lowered to $120.00 at TD Cowen

TransMedics Group (NASDAQ:TMDX) had its price objective reduced by research analysts at TD Cowen from $175.00 to $120.00 in a report issued on Monday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. TD Cowen’s target price suggests a potential upside of 48.64% from the stock’s current price.

A number of other research analysts have also commented on TMDX. Oppenheimer dropped their price objective on shares of TransMedics Group from $200.00 to $125.00 and set an “outperform” rating on the stock in a research note on Tuesday, October 29th. Stephens lifted their target price on shares of TransMedics Group from $151.00 to $178.00 and gave the company an “overweight” rating in a report on Friday, August 2nd. JPMorgan Chase & Co. lowered their target price on shares of TransMedics Group from $173.00 to $116.00 and set an “overweight” rating on the stock in a report on Tuesday, October 29th. Needham & Company LLC lowered their target price on shares of TransMedics Group from $208.00 to $109.00 and set a “buy” rating on the stock in a report on Tuesday, October 29th. Finally, Baird R W raised shares of TransMedics Group to a “strong-buy” rating in a report on Tuesday, September 24th. One analyst has rated the stock with a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, TransMedics Group has an average rating of “Buy” and a consensus target price of $139.30.

TransMedics Group Stock Performance

NASDAQ TMDX traded up $0.25 during trading on Monday, reaching $80.73. The company’s stock had a trading volume of 1,044,163 shares, compared to its average volume of 969,998. The company has a debt-to-equity ratio of 2.42, a quick ratio of 7.33 and a current ratio of 8.20. The firm has a market cap of $2.71 billion, a price-to-earnings ratio of 85.88 and a beta of 2.08. TransMedics Group has a twelve month low of $66.76 and a twelve month high of $177.37. The business’s fifty day moving average price is $125.63 and its 200-day moving average price is $139.55.

TransMedics Group (NASDAQ:TMDX) last posted its quarterly earnings data on Monday, October 28th. The company reported $0.12 EPS for the quarter, missing analysts’ consensus estimates of $0.29 by ($0.17). The business had revenue of $108.76 million during the quarter, compared to analyst estimates of $115.00 million. TransMedics Group had a net margin of 8.14% and a return on equity of 18.74%. The company’s revenue for the quarter was up 63.7% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.12) earnings per share. As a group, analysts anticipate that TransMedics Group will post 1.07 EPS for the current fiscal year.

Insider Activity at TransMedics Group

In other TransMedics Group news, insider Tamer I. Khayal sold 2,958 shares of the firm’s stock in a transaction on Tuesday, October 1st. The shares were sold at an average price of $148.24, for a total transaction of $438,493.92. Following the completion of the transaction, the insider now directly owns 20,843 shares of the company’s stock, valued at $3,089,766.32. This trade represents a 12.43 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Waleed H. Hassanein sold 8,625 shares of TransMedics Group stock in a transaction dated Monday, September 16th. The shares were sold at an average price of $153.42, for a total transaction of $1,323,247.50. Following the completion of the transaction, the chief executive officer now directly owns 61,643 shares of the company’s stock, valued at $9,457,269.06. This trade represents a 12.27 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 36,958 shares of company stock valued at $5,230,528. Corporate insiders own 7.00% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of the business. Vaughan Nelson Investment Management L.P. bought a new stake in TransMedics Group in the 2nd quarter valued at about $39,862,000. Driehaus Capital Management LLC raised its position in shares of TransMedics Group by 15.8% during the 2nd quarter. Driehaus Capital Management LLC now owns 1,486,073 shares of the company’s stock worth $223,832,000 after buying an additional 202,867 shares in the last quarter. Principal Financial Group Inc. raised its position in shares of TransMedics Group by 260.1% during the 3rd quarter. Principal Financial Group Inc. now owns 202,287 shares of the company’s stock worth $31,759,000 after buying an additional 146,115 shares in the last quarter. Hood River Capital Management LLC bought a new stake in shares of TransMedics Group during the 2nd quarter worth about $18,854,000. Finally, Canada Pension Plan Investment Board bought a new stake in shares of TransMedics Group during the 2nd quarter worth about $16,086,000. 99.67% of the stock is owned by institutional investors and hedge funds.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.